Technology Highlights
JCM-16021: A Novel Multi-Target Chinese Medicine for Durable Management of Irritable Bowel Syndrome
Key Highlights
- Novel Chinese medicine formula JCM-16021 developed for prevention and treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
- Demonstrated efficacy in alleviating diarrhea and abdominal pain
- Supported by preclinical studies and Phase II clinical trials
- Addresses unmet clinical needs in IBS-D treatment with lower recurrence and fewer side effects
Challenges
- IBS-D affects 10–20% of the global population and significantly reduces the quality of life
- Conventional Western treatments focus on transient symptom control, often resulting in limited efficacy and high recurrence
- Long-term pharmacological management is associated with side effects and poor patient compliance
Breakthrough Technology
- Optimised from a classical Chinese medicine prescription using evidence-based pharmacological and clinical research
- Multi-target, multi-pathway mechanism regulating intestinal motility and inflammation, while alleviating visceral hypersensitivity via a novel butyrate-producing pathway
- Proven symptom improvement after 8 weeks of treatment with sustained effects remaining even after discontinuation
- Patented formulation with regulatory approval for clinical trials in both Hong Kong and the Chinese Mainland
Industry Applications
- Gastrointestinal therapeutics
- Preventive and integrative medicine
- Chinese medicine based drug development
- Hospital, outpatient and primary care IBS management
Business Benefits
- Large and growing IBS patient market with unmet clinical needs
- Patented formulation with strong IP protection
- Lower recurrence enhances long term patient retention
- Strong commercialisation potential via licensing to pharmaceutical companies
Team Leader
Professor Bian Zhaoxiang, Associate Vice-President (Clinical Chinese Medicine); Chair Professor and Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, School of Chinese Medicine; Director, Centre for Chinese Herbal Medicine Drug Development Limited
Interested in Our Innovation?
Contact us at iit@hkbu.edu.hk to explore collaboration and partnership opportunities.